PEA (Palmitoylethanolamide)

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide belonging to the N-acylethanolamine family, synthesized on demand from membrane phospholipid precursors via a two-step enzymatic process involving N-palmitoyltransferase and N-acylphosphatidylethanolamine phospholipase D. It is produced locally in response to cellular stress, injury, or inflammatory stimuli.

The primary pharmacological target is the nuclear receptor peroxisome proliferator-activated receptor-alpha (PPAR-alpha). Upon binding, PEA activates PPAR-alpha transcriptional programs that suppress the NF-kB and p38-MAPK signaling cascades, reducing downstream production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. The necessity of this pathway has been established directly: in PPAR-alpha knockout mice subjected to sciatic nerve constriction injury, PEA failed to reduce hyperalgesia, allodynia, or macrophage infiltration, whereas it was fully effective in wild-type animals.

PEA also modulates the endocannabinoid system through an indirect mechanism termed the "entourage effect." It inhibits fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide, thereby elevating endogenous anandamide levels and amplifying cannabinoid receptor signaling without directly binding CB1 or CB2.

Additional targets include GPR55, GPR119, and the transient receptor potential vanilloid 1 channel (TRPV1); activation of TRPV1 leads to receptor desensitization and reduced sensory neuron excitability. At the cellular level, PEA stabilizes mast cells, reducing histamine and pro-inflammatory mediator release, and attenuates reactive microglia and astrocyte activation in the central nervous system.

The best available evidence comes from a 2023 systematic review and meta-analysis (Lang-Illievich et al., Nutrients) that identified 11 double-blind randomized controlled trials enrolling 774 patients with diverse chronic pain conditions including neuropathic pain, musculoskeletal disorders, gynecological pain, and irritable bowel syndrome. PEA reduced pain intensity with a standardized mean difference of 1.68 (95% CI 1.05 to 2.31, p=0.00001) relative to comparators, with nine of eleven trials reporting significant analgesic benefit. Dosages ranged from 300 to 1200 mg per day, and no clear dose-response relationship was identified.

A key positive trial: a single-centre, quadruple-blind, placebo-controlled RCT (n=70, 94% completion) administered 600 mg PEA daily for 8 weeks in participants with diabetic peripheral neuropathic pain. The PEA group showed significant reductions in BPI-DPN total pain and pain interference scores and in NPSI total score versus placebo (p less than or equal to 0.001), alongside reduced IL-6 and C-reactive protein, improved sleep, and improved depression scores.

A double-blind RCT in spinal cord injury neuropathic pain (n=73, 12 weeks, ultramicronized PEA as add-on therapy) produced a negative result: no significant difference in mean pain intensity versus placebo (p=0.46), with both groups showing minimal change. This trial is important context against overstating efficacy.

A double-blind RCT using 600 mg of water-dispersed PEA for acute migraine episodes (n=80 enrolled, 64 completing with events) found significantly more migraines resolving at 2 hours and 8 hours in the PEA group versus placebo, with substantially reduced rescue analgesic use and no adverse events in either group.

Preclinical evidence is extensive, including the PPAR-alpha knockout mouse chronic constriction injury model that established mechanistic necessity. Evidence in fibromyalgia, osteoarthritis, endometriosis-related pain, and postoperative pain exists primarily from smaller trials and observational studies.

Typical dosage: 300-600 mg (twice daily).

Clinical trials have used a range of 300 to 1200 mg per day in oral formulations, most commonly divided into two doses. The most widely studied dosage for chronic neuropathic pain is 600 mg twice daily (1200 mg per day), the schedule used with the Normast brand of ultramicronized PEA (umPEA) in multiple European trials. For diabetic neuropathic pain, 600 mg once daily for 8 weeks showed significant benefit in one RCT.

Formulation matters substantially. Standard (non-micronized) PEA has limited aqueous solubility and variable oral bioavailability. Micronized PEA (particle size reduced to the micron range) and ultramicronized PEA (below 10 micrometers) show markedly improved gastrointestinal absorption. Newer water-dispersed formulations (e.g., LipiSperse technology, branded as Levagen+) may achieve effective tissue concentrations at lower doses in the 300 to 600 mg per day range.

Trial durations have ranged from 8 weeks to 12 months; a 2024 extended-treatment meta-analysis found greater pain reductions at 60 days than at 30 days, suggesting benefit may accumulate over time.

Dosage in migraine: one RCT used a single 600 mg dose at headache onset, with a second dose permitted at 2 hours if needed.

No established therapeutic dose has been set by a regulatory authority, as PEA is sold as a food supplement or medical food in most jurisdictions rather than as a licensed drug.

This information is provided for educational reference only and does not constitute medical advice. Anyone considering PEA for a medical condition should consult a qualified healthcare provider.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

PEA is most frequently studied and used alongside luteolin, a flavonoid antioxidant. Co-ultramicronized PEA-luteolin (marketed as Glialia) has been investigated in neurological and inflammatory pain contexts; preclinical data show the combination reduces pro-inflammatory cytokines and oxidative-nitrosative stress beyond either agent alone, attributed to luteolin's PPAR-gamma agonism and free radical scavenging complementing PEA's PPAR-alpha activity. This synergy has reasonable mechanistic grounding, though the clinical trial base for the combination specifically is limited.

PEA has been combined with alpha-lipoic acid (an antioxidant with documented neuroprotective properties in diabetic neuropathy) in a commercial formulation that also included superoxide dismutase, vitamins, magnesium, and zinc; a study reported a 33% reduction in neuropathic pain scores, though this compound formulation makes it difficult to attribute outcomes to PEA alone.

Combination with L-acetylcarnitine has been proposed for neuropathic pain, with patent literature claiming synergistic clearance of pain signals, but clinical evidence for this pairing is sparse.

PEA has been compared head-to-head (not combined) with pregabalin plus nortriptyline in a trigeminal neuropathy RCT, with similar outcomes reported.

All combination strategies described above are supported by limited or preliminary clinical evidence. Combination use for enhanced pain relief is largely anecdotal or inferred from mechanistic plausibility, and none of these combinations carry regulatory approval.

PEA (Palmitoylethanolamide) is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Very safe, minimal side effects

PEA has a well-documented safety profile accumulated across more than 20 clinical trials and preclinical toxicology studies. Across 774 patients in the 2023 meta-analysis, only one trial reported adverse effects, describing mild and transient gastrointestinal symptoms (nausea, stomach discomfort). No serious adverse events have been attributed to PEA in published human studies.

Formal toxicology work on micronized PEA (microPEA) established a No Observed Effect Level (NOEL) at 1000 mg per kg body weight per day in 90-day rodent studies, the highest dose tested. Bacterial reverse mutation assays (Ames test in five strains) and in vitro micronucleus testing found no mutagenic or clastogenic activity, indicating no genotoxic potential.

PEA degrades enzymatically via FAAH and N-acylethanolamine acid amidase (NAAA) to palmitic acid and ethanolamine, both endogenous compounds with no pharmacotoxicological activity.

No documented drug-drug interactions have been identified in the published literature, making PEA theoretically suitable as an add-on to conventional analgesics, anticonvulsants, or antidepressants, though formal interaction studies are absent.

Contraindications: none formally established. Caution is warranted and supplementation is generally not recommended during pregnancy or breastfeeding due to lack of safety data in those populations. PEA is not a controlled substance under any major regulatory framework.

The compound does not carry the gastrointestinal bleeding, cardiovascular, or renal risks associated with chronic NSAID use, and lacks the dependency or sedation concerns of opioids or gabapentinoids.